Title:
FIBRIC ACID COMPOUND AND MEDICAL USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2020/038464
Kind Code:
A1
Abstract:
A fibric acid compound, pharmaceutically acceptable salts or esters, stereoisomers, prodrugs, hydrates, solvates, and crystal forms thereof, metabolite forms thereof or any combination or mixture thereof; a pharmaceutical composition containing the compound, the pharmaceutically acceptable salts or esters, stereoisomers, prodrugs, hydrates, solvates, and crystal forms thereof, the metabolite forms thereof or any combination or mixture thereof; and medical use of the compound, the pharmaceutically acceptable salts or esters, stereoisomers, prodrugs, hydrates, solvates, and crystal forms thereof, the metabolite forms thereof or any combination or mixture thereof. These can be used for preventing and/or treating metabolic diseases, such as metabolic syndromes, non-alcoholic fatty liver diseases, and/or diabetes.
More Like This:
Inventors:
JIAO NING (CN)
YU SIWANG (CN)
SONG SONG (CN)
LIU YAMENG (CN)
YANG SIMIN (CN)
YU SIWANG (CN)
SONG SONG (CN)
LIU YAMENG (CN)
YANG SIMIN (CN)
Application Number:
PCT/CN2019/102273
Publication Date:
February 27, 2020
Filing Date:
August 23, 2019
Export Citation:
Assignee:
BEIJING WHOLESOMEYIRD SCI & TECH CO LTD (CN)
International Classes:
C07C59/68; A61K31/185; A61K31/275; A61P3/10; C07C51/09
Domestic Patent References:
| WO1999000353A1 | 1999-01-07 | |||
| WO1997012615A1 | 1997-04-10 | |||
| WO1997012613A1 | 1997-04-10 | |||
| WO1996038144A1 | 1996-12-05 |
Foreign References:
| US3674836A | 1972-07-04 | |||
| US3707566A | 1972-12-26 | |||
| US3847994A | 1974-11-12 | |||
| US3759986A | 1973-09-18 | |||
| US5712396A | 1998-01-27 |
Other References:
CREGER, P.: "Structure/Activity Relationship of Gemfibrozil (CI-719) and Related Compounds", PROC. ROY. SOC. MED., vol. 12, 1976, pages 31, XP055687343
DATABASE CAS 14 November 2017 (2017-11-14), retrieved from STN Database accession no. 2142154-52-5
HOOVER, JOHN E.: "Remington's Pharmaceutical Sciences", 1995, MACK PUBLISHING COMPANY
LIBERMAN ET AL.: "Pharmaceutical Dosage Forms", 1980, MARCEL DECKER
KIBBE ET AL.: "Handbook of Pharmaceutical Excipients", 1999, AMERICAN PHARMACEUTICAL ASSOCIATION
T HIGUCHIW STELLA: "Pro-drugs as Novel Delivery Systems", ACS SYMPOSIUM SERIES, vol. 14
"Bioreversible Carriers in Drug Design", 1987, PERGAMON PRESS
REDDY PLENT-SCHOCHET DRAMAKRISHNAN NMCLAUGHLIN MJIALAL I: "Metabolic syndrome is an inflammatory disorder: A conspiracy between adipose tissue and phagocytes", CLIN CHIM ACTA, vol. 496, 2019, pages 35 - 44
CHEN ZYU RXIONG YDU FZHU S: "A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease", LIPIDS HEALTH DIS, vol. 16, 2017, pages 203
CATRYSSE LVAN LOO G: "Inflammation and the Metabolic Syndrome: The Tissue-Specific Functions of NF-kappaB", TRENDS CELL BIOL, vol. 27, 2017, pages 417 - 429, XP085028230, DOI: 10.1016/j.tcb.2017.01.006
ESSER NPAQUOT NSCHEEN AJ: "Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease", EXPERT OPIN INVESTIG DRUGS, vol. 24, 2015, pages 283 - 307
CHARTOUMPEKIS DVKENSLER TW: "New player on an old field; the keapl/Nrf2 pathway as a target for treatment of type 2 diabetes and metabolic syndrome", CURR DIABETES REV, vol. 9, 2013, pages 137 - 145
CHOWDHRY SNAZMY MHMEAKIN PJDINKOVA-KOSTOVA ATWALSH SVTSUJITA TDILLON JF ET AL.: "Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis", FREE RADIC BIOL MED, vol. 48, 2010, pages 357 - 371, XP026820730
SANTOS JCVALENTIM IBDE ARAUJO ORATAIDE TDA RGOULART MO: "Development of nonalcoholic hepatopathy: contributions of oxidative stress and advanced glycation end products", INT J MOL SCI, vol. 14, 2013, pages 19846 - 19866
SHIMOZONO RASAOKA YYOSHIZAWA YAOKI TNODA HYAMADA MKAINO M ET AL.: "Nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat mode", MOL PHARMACOL, vol. 84, 2013, pages 62 - 70, XP055516110, DOI: 10.1124/mol.112.084269
SPAHIS SDELVIN EBORYS JMLEVY E: "Oxidative Stress as a Critical Factor in Nonalcoholic Fatty Liver Disease Pathogenesis", ANTIOXID REDOX SIGNAL, vol. 26, 2017, pages 519 - 541
See also references of EP 3842410A4
DATABASE CAS 14 November 2017 (2017-11-14), retrieved from STN Database accession no. 2142154-52-5
HOOVER, JOHN E.: "Remington's Pharmaceutical Sciences", 1995, MACK PUBLISHING COMPANY
LIBERMAN ET AL.: "Pharmaceutical Dosage Forms", 1980, MARCEL DECKER
KIBBE ET AL.: "Handbook of Pharmaceutical Excipients", 1999, AMERICAN PHARMACEUTICAL ASSOCIATION
T HIGUCHIW STELLA: "Pro-drugs as Novel Delivery Systems", ACS SYMPOSIUM SERIES, vol. 14
"Bioreversible Carriers in Drug Design", 1987, PERGAMON PRESS
REDDY PLENT-SCHOCHET DRAMAKRISHNAN NMCLAUGHLIN MJIALAL I: "Metabolic syndrome is an inflammatory disorder: A conspiracy between adipose tissue and phagocytes", CLIN CHIM ACTA, vol. 496, 2019, pages 35 - 44
CHEN ZYU RXIONG YDU FZHU S: "A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease", LIPIDS HEALTH DIS, vol. 16, 2017, pages 203
CATRYSSE LVAN LOO G: "Inflammation and the Metabolic Syndrome: The Tissue-Specific Functions of NF-kappaB", TRENDS CELL BIOL, vol. 27, 2017, pages 417 - 429, XP085028230, DOI: 10.1016/j.tcb.2017.01.006
ESSER NPAQUOT NSCHEEN AJ: "Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease", EXPERT OPIN INVESTIG DRUGS, vol. 24, 2015, pages 283 - 307
CHARTOUMPEKIS DVKENSLER TW: "New player on an old field; the keapl/Nrf2 pathway as a target for treatment of type 2 diabetes and metabolic syndrome", CURR DIABETES REV, vol. 9, 2013, pages 137 - 145
CHOWDHRY SNAZMY MHMEAKIN PJDINKOVA-KOSTOVA ATWALSH SVTSUJITA TDILLON JF ET AL.: "Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis", FREE RADIC BIOL MED, vol. 48, 2010, pages 357 - 371, XP026820730
SANTOS JCVALENTIM IBDE ARAUJO ORATAIDE TDA RGOULART MO: "Development of nonalcoholic hepatopathy: contributions of oxidative stress and advanced glycation end products", INT J MOL SCI, vol. 14, 2013, pages 19846 - 19866
SHIMOZONO RASAOKA YYOSHIZAWA YAOKI TNODA HYAMADA MKAINO M ET AL.: "Nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat mode", MOL PHARMACOL, vol. 84, 2013, pages 62 - 70, XP055516110, DOI: 10.1124/mol.112.084269
SPAHIS SDELVIN EBORYS JMLEVY E: "Oxidative Stress as a Critical Factor in Nonalcoholic Fatty Liver Disease Pathogenesis", ANTIOXID REDOX SIGNAL, vol. 26, 2017, pages 519 - 541
See also references of EP 3842410A4
Attorney, Agent or Firm:
CCPIT PATENT AND TRADEMARK LAW OFFICE (CN)
Download PDF:
Previous Patent: OPTICAL FINGERPRINT IDENTIFICATION CIRCUIT
Next Patent: CODING TRANSFORM COEFFICIENTS WITH THROUGHPUT CONSTRAINTS
Next Patent: CODING TRANSFORM COEFFICIENTS WITH THROUGHPUT CONSTRAINTS